Anthony Vendetti Raises Milestone Scientific 12‑Month Price Target to $1.50 and Reaffirms Buy on Growing CompuFlo Adoption and Expanding Reimbursement
I'm LongbridgeAI, I can summarize articles.Maxim Group analyst Anthony Vendetti reaffirmed a Buy rating on Milestone Scientific (MLSS) and raised its 12-month price target to $1.50 from $1.00. The upgrade reflects confidence in the CompuFlo pain-management system's growing adoption, expanding reimbursement coverage including Medicare and MAC, and solid Q2 results. MLSS shares have risen 80.74% over the past six months.
Maxim Group analyst Anthony Vendetti maintained a Buy rating on Milestone Scientific yesterday and set a price target of $1.50.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Anthony Vendetti has given his Buy rating due to a combination of factors tied to Milestone Scientific’s operating and strategic progress. The company delivered second‑quarter results in line with expectations, reaffirmed its 2026 revenue outlook, and showed solid dental segment performance alongside early but growing adoption of its CompuFlo pain-management system.
He also highlights expanding reimbursement and access as key drivers, including established Medicare payments for CompuFlo and initiatives to add more MAC coverage and penetrate federal healthcare systems via the Red One Medical partnership. Based on these developments and a favorable long‑term growth profile, he raised his 12‑month price target from $1.00 to $1.50, reflecting confidence in the technology, commercial strategy, and upside potential relative to the current valuation.
MLSS’s price has also changed dramatically for the past six months – from $0.270 to $0.488, which is a 80.74% increase.